7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer,
which is the leading cause of death worldwide with the majority of patients presenting with …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Background In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Background Erlotinib is approved for the treatment of all patients with advanced non-small-
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC …